clinical trial · NCT04921345
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Galderma R&D·phase2·completed·n = 105
Moderate-to-Severe Atopic DermatitisNemolizumabNemolizumab
brief summary
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
started
Jun 24, 2021
primary completion
Apr 28, 2025
completion
Apr 28, 2025
last updated
Jul 18, 2025
official title
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (Aged 2 to 11 Years) With Moderate-to-Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol